Cosmos Health Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held on July 15, 2026. Cosmos Health Inc. (Nasdaq: COSM), incorporated in Nevada with principal offices in Thessaloniki, Greece, reported the results of shareholder votes and corporate governance actions taken during the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Corporate Actions
- Board Elections: Six directors were elected to serve until the next Annual Meeting: Grigorios Siokas, Demetrios G. Demetriades, John J. Hoidas, Dr. Anastasios Aslidis, Suhel Bhutawala, and Theodoros C. Karkantzos.
- Preferred Stock Issuance: Shareholders approved the issuance and designation of 100,000 shares of Series B Preferred Stock. A Certificate of Designation will be filed with the Nevada Secretary of State.
- Equity Plan: The 2026 Equity Omnibus Plan was approved by shareholders.
- Auditor Ratification: The appointment of the Independent Registered Public Accounting Firm was ratified.
Voting Results and Management Commentary
Of the 60,043,491 shares outstanding, 28,315,417 shares (approximately 47%) were present in person or by proxy. All proposals submitted to the vote passed.
| Proposal | Votes For | Votes Against | Affirmative % |
|---|---|---|---|
| Election of Directors (Aggregate) | Varies by candidate | Varies by candidate | 79.07% - 84.22% |
| Ratification of Auditors | 23,852,605 | 4,391,554 | 84.24% |
| 2026 Equity Omnibus Plan | 22,534,586 | 5,673,149 | 79.58% |
| Series B Preferred Stock Issuance | 22,363,076 | 5,818,559 | 78.98% |
The filing does not contain specific management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Verify the specific rights, preferences, and restrictions of the newly authorized 100,000 shares of Series B Preferred Stock in the Certificate of Designation (Exhibit 3.1).
- Review the Definitive Proxy Statement filed on June 2, 2026, for detailed terms regarding the Series B Preferred Stock and the 2026 Equity Omnibus Plan.
- Confirm the identity of the newly elected directors and their independence status.
- Note that approximately 53% of outstanding shares were not represented at the Annual Meeting.